

EXHIBIT 17

Page 1

1 IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

3 IN RE JOHNSON & JOHNSON TALCUM)
POWDER PRODUCTS MARKETING,) MDL NO.
4 SALES PRACTICIES, AND PRODUCTS) 16-2738 (MAS) (RLS)
LIABILITY LITIGATION

7 ORAL DEPOSITION OF
8 JUDITH WOLF, M.D.
9 APRIL 25, 2024
10 (VOLUME 2)

Page 30	Page 32
1 about probably account for the vast majority of 09:34 2 inherited ovarian cancers. 09:34	1 ovarian cancer? 09:37 2 MRS. O'DELL: Object to the form. 09:37
3 Q. From your -- from the research that you did on 09:35 4 the SDHA and PTCH1 genes, is it your opinion that 09:35 5 medical science has researched those genes sufficiently 09:35 6 as it relates to ovarian cancer to rule out that they 09:35 7 can affect the risk of developing ovarian cancer? 09:35	3 A. The tests that she had tested for 67, which is 09:37 4 probably the most, one of the most, number of genes that 09:37 5 we know of at the time she had testing in 2019 that were 09:37 6 available. 09:37 7 And as I stated before, since we've known 09:37
8 MRS. O'DELL: Object to the form. 09:35	8 about these mutations, the vast majority of them are 09:37
9 A. It's my opinion that to date there's no 09:35 10 evidence that mutation in SDHA has any increased risk of 09:35 11 ovarian cancer. It's also my opinion that the PTCH1 09:35 12 gene mutation that she had was a VUS and the vast 09:35 13 majorities, they're not found to be associated with 09:35 14 anything. And of the pathologic mutations in PTCH1, to 09:35 15 date, there hasn't been any association with ovarian 09:35 16 cancer. So I think it's highly unlikely. 09:35	9 inherited ovarian cancers or associated with BRCA1 and 09:38 10 2. And all the other genes that have been identified 09:38 11 since then account for very small portion of inherited 09:38 12 ovarian cancers. So could she have a mutation that 09:38 13 wasn't tested for? It's possible. Is it likely? No. 09:38 14 Q. (By Mr. Hegarty) Do you agree though that based 09:38 15 on your review of Mrs. Bondurant's records, it was 09:38 16 appropriate for her to have genetic testing? 09:38
17 Q. (By Mr. Hegarty) When you were doing your 09:35 18 research into those two gene mutations, did you see 09:35 19 whether there has been any analysis done as to those 09:36 20 mutations and ovarian cancer? 09:36	17 A. I do think it was appropriate for her to have 09:38 18 genetic testing. In fact, I refer all of my ovarian 09:38 19 cancer patients today to have genetic testing or at 09:38 20 least offer it to them. 09:38
21 A. I'm not aware of that. 09:36	21 Q. So if she had been your patient at the time of 09:38
22 Q. You note in your report for Mrs. Bondurant on 09:36 23 Page 23 that her family history includes a maternal aunt 09:36 24 with [REDACTED] and a mother with [REDACTED] 09:36	22 diagnosis, you would've recommended she have genetic 09:38 23 testing? 09:38
25 Correct? 09:36	24 A. I don't remember what year she was diagnosed. 09:38 25 I'm going to say in 2024, I certainly would recommend 09:38
Page 31	Page 33
1 A. Yes. 09:36	1 everyone. 09:38
2 Q. You go on to say that a family history like 09:36 3 this was a risk factor for Mrs. Bondurant in developing 09:36 4 breast cancer up to 2.0 or two times. Correct? 09:36	2 Q. Please feel free to look at your report. 09:38
5 A. Yes. 09:36	3 A. Yeah, in 2018, 2018, she was diagnosed in late 09:38 4 2018. So I think even at that time, I was recommending 09:39 5 everyone have genetic testing. 09:39
6 Q. I should say two times or 2.0. Right? 09:36	6 Q. Have you seen patients as follow up to their 09:39 7 original cancer diagnosis where they had less than full 09:39 8 panel testing years earlier that you recommend be 09:39 9 retested with the now full panel testing? 09:39
7 A. Correct. 09:36	10 A. It's a discussion that I've had with a few 09:39 11 patients. It's a complicated issue, I think, because 09:39 12 oftentimes it's an expensive test that insurance will 09:39 13 pay for a new test. And if they already have the 09:39 14 diagnosis and they've tested negative for at least BRCA1 09:39 15 and 2, putting them through the cost of a four to 09:39 16 6,000-dollar test may or may not be of benefit. 09:39
8 Q. Based on this risk tied to family history, do 09:36 9 you agree that it does raise the issue of whether Mrs. 09:36 10 Bondurant has some type of inherited gene mutation 09:36 11 related to ovarian cancer risk? True? 09:36	17 So it's an individual discussion that I 09:39 18 have with patients and I've had a few go ahead and get 09:39 19 tested and some that don't want to get more testing. 09:39
12 A. It's hard to know. That could be one reason 09:36 13 for her increased family risk. It also could be 09:37 14 something else that the family was exposed to that put 09:37 15 them at an increased risk that they were all exposed to. 09:37 16 That's all I can say about it, what's in the literature 09:37 17 about family history when testing is negative and that's 09:37 18 a possibility. 09:37	20 Q. Turning to Page 22 of Dr. Levy's report, he 09:40 21 discusses his review of Anna Gallardo, the genetic 09:40 22 testing results. Correct? 09:40
19 Q. Do you agree that Mrs. Bondurant could have an 09:37 20 inherited gene mutation that she was not tested for back 09:37 21 in 2019? 09:37	23 A. Yes. 09:40
22 A. I think it's unlikely. It's a possibility, but 09:37 23 I think it's highly unlikely. 09:37	24 Q. I will mark as our next exhibit your report 09:40 25 from Mrs. Gallardo and her genetic test result. 09:40
24 Q. Is it fair to say that the tests that she had 09:37 25 couldn't rule out a gene mutation being involved in her 09:37	

<p>1 Q. And all that is still accurate? 11:16 2 A. Yes. 11:16 3 MR. HEGARTY: Those are all the questions I 11:16 4 have. 11:16 5 RECROSS-EXAMINATION 11:16 6 BY MRS. O'DELL: 11:16 7 Q. One last follow up. In addition to the 11:16 8 specific references in your report to asbestos and 11:16 9 studies that are pinpoint cited or specifically 11:16 10 referenced in the body of your report, do you also rely 11:16 11 on all the literature regarding asbestos as included in 11:16 12 your materials considered? 11:16 13 A. Yes. 11:16 14 MRS. O'DELL: Thank you. Nothing further. 11:16 15 MR. HEGARTY: No further questions. 11:16 16 COURT REPORTER: Mrs. O'Dell, were you 17 going to want a copy of this transcript? 18 MRS. O'DELL: Yes, please. 19 COURT REPORTER: And Mr. Golomb? 20 MR. GOLOMB: I do. 21 (Deposition concluded at 11:16 a.m.) 22 *-*SIGNATURE REQUESTED*-* 23 24 25 </p>	<p>Page 90</p> <p>1 I, JUDITH WOLF, M.D., have read the foregoing 2 deposition and hereby affix my signature that same is 3 true and correct, except as noted above. 4 5 6 _____ 7 JUDITH WOLF, M.D. 8 THE STATE OF _____ 9 COUNTY OF _____ 10 Before me, _____, on 11 this day personally appeared JUDITH WOLF, M.D., known to 12 me (or proved to me under oath or through 13 _____) (description of identity card or 14 other document) to be the person whose name is 15 subscribed to the foregoing instrument and acknowledged 16 to me that they executed the same for the purposes and 17 consideration therein expressed. 18 Given under my hand and seal of office this 19 _____ day of _____, 2024. 20 21 22 _____ 23 Notary Public in and for 24 The State of 25 </p>
<p>1 CHANGES AND SIGNATURE 2 WITNESS NAME: _____ DATE OF DEPOSITION: _____ 3 PAGE LINE CHANGE REASON 4 _____ 5 _____ 6 _____ 7 _____ 8 _____ 9 _____ 10 _____ 11 _____ 12 _____ 13 _____ 14 _____ 15 _____ 16 _____ 17 _____ 18 _____ 19 _____ 20 _____ 21 _____ 22 _____ 23 _____ 24 _____ 25 _____ </p>	<p>Page 91</p> <p>1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY 2 3 IN RE JOHNSON & JOHNSON TALCUM) POWDER PRODUCTS MARKETING,) MDL NO. 4 SALES PRACTICES, AND PRODUCTS) 16-2738 (MAS) (RLS) 5 REPORTER'S CERTIFICATION DEPOSITION OF JUDITH WOLF, M.D. 6 April 25, 2024 7 I, Gabriela S. Silva, Certified Shorthand 8 Reporter in and for the State of Texas, hereby certify to the following: 9 That the witness, JUDITH WOLF, M.D., was duly 10 sworn by the officer and that the transcript of the oral deposition is a true record of the testimony given by 11 the witness; 12 I further certify that pursuant to FRCP Rule 30(f)(1) that the signature of the deponent: 13 _____ X _____ was requested by the deponent or a party 14 before the completion of the deposition and that the signature is to be before any notary public and returned 15 within 30 days from date of receipt of the transcript. If returned, the attached Changes and Signature Page 16 contains any changes and the reasons therefor; 17 _____ was not requested by the deponent or a party before the completion of the deposition. 18 I further certify that I am neither counsel 19 for, related to, nor employed by any of the parties or attorney in the action in which this proceeding was 20 taken, and further that I am not financially or otherwise interested in the outcome of the action. 21 22 Certified to by me this _____ day of _____, 2024. 23 24 <%23035.Signature%> 25 </p>

24 (Pages 90 - 93)